ARDX · NASDAQ · Biotechnology

Ardelyx (ARDX)

Commercializes IBSRELA and XPHOZAH from a gut-local NHE3 inhibition platform.

$3.59
After-hours close−0.04 (−1.21%)
At close$3.63(+3.71%)